Biogen Inc.
BIIB · NASDAQ
Company research
Biogen Inc. (NASDAQ: BIIB) is a global biopharmaceutical company founded in 1978 and headquartered in Cambridge, Massachusetts, that specializes in discovering, developing, manufacturing, and delivering innovative therapies for neurological, neurodegenerative, and rare diseases. The company maintains a broad portfolio of treatments addressing multiple sclerosis (including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI), spinal muscular atrophy (SPINRAZA), Friedreich's Ataxia (SKYCLARYS), amyotrophic lateral sclerosis (QALSODY), and Alzheimer's disease (LEQEMBI), alongside a growing biosimilar segment featuring products such as BENEPALI, IMRALDI, and FLIXABI. Under the leadership of CEO Christopher A. Viehbacher, Biogen actively pursues an extensive research and development pipeline targeting conditions ranging from Parkinson's disease and neuropsychiatric disorders to immunology and neuropathic pain, supported by strategic collaborations with partners including Eisai, Genentech, Ionis Pharmaceuticals, and Sage Therapeutics. With approximately 7,605 full-time employees and a market capitalization of approximately $29.6 billion, Biogen remains one of the most established and influential pioneers in the global biotechnology and biopharmaceutical landscape.
Research reports
Intellectia AI · May 22, 2026Should You Buy Biogen Inc (BIIB) Today? Analysis, Price Targets, and 2026 Outlook
Intellectia’s weekly “Should I Buy” note assigns BIIB a Hold, citing meaningful upside potential from Wall Street price targets and pipeline optimism but advising investors to wait due to weak technical momentum, recent trial failures, aggressive insider selling, and ongoing legal headline risk.
BusinessQuant · April 8, 2026Biogen Inc. (BIIB) Stock Analysis and MetricsBusinessQuant presents a balanced bull and bear thesis: growth products and new launches like LEQEMBI, SKYCLARYS, and lupus/nephrology assets support a long-term “bridge to growth,” while mid-single-digit revenue declines, dependence on future reimbursement decisions, high one-time charges, regulatory uncertainty across late-stage programs, and potential supply chain/pricing risks temper the outlook.
StockStory · March 30, 2026Biogen (BIIB) Research Report: Q4 CY2025 UpdateStockStory’s analyst team rates Biogen “Underperform,” arguing that multi-year revenue and EPS declines, negative operating margin in Q4, and falling ROIC make the business low quality despite healthy historical margins, and concluding that even a seemingly cheap forward P/E around 12.2x and a consensus one-year target modestly above the current price do not justify owning the stock.
Rockflow.ai · March 29, 2026Biogen Inc. (BIIB) Stock AnalysisRockflow’s AI-driven report judges BIIB as unattractive at current levels, highlighting an operating loss, negative profitability metrics, inefficient operations, and a very high EV/EBITDA and deeply negative forward P/E that appear to price in a challenging turnaround, and recommends investors wait for clearer evidence of sustained earnings recovery and successful commercialization of new therapies before buying.
GuruFocus Via Yahoo Finance · February 6, 2026Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst …This GuruFocus earnings-analysis article, published on Yahoo Finance, emphasizes Biogen’s robust 2025 finish with revenue and EPS beats, 19% growth in “growth products,” strong free cash flow and cash balances, and leading market share for LEQEMBI, while acknowledging expected mid-single-digit revenue declines in 2026, MS franchise erosion, reimbursement challenges, and execution risks around new therapeutic areas and business development.